These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25531363)

  • 1. Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatment.
    Laharie D
    Dig Dis; 2014; 32 Suppl 1():116-21. PubMed ID: 25531363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Previous cancer and/or lymphoma in patients with refractory IBD--con: anti-TNF or conventional immunosuppressive treatment.
    Mantzaris GJ
    Dig Dis; 2014; 32 Suppl 1():122-7. PubMed ID: 25531364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.
    Poullenot F; Seksik P; Beaugerie L; Amiot A; Nachury M; Abitbol V; Stefanescu C; Reenaers C; Fumery M; Pelletier AL; Nancey S; Peyrin-Biroulet L; Bourreille A; Hébuterne X; Brixi H; Savoye G; Lourenço N; Altwegg R; Buisson A; Cazelles-Boudier C; Racine A; Vergniol J; Laharie D;
    Inflamm Bowel Dis; 2016 Jun; 22(6):1362-9. PubMed ID: 26919458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy.
    Poullenot F; Laharie D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States.
    Lin KK; Sewell JL
    Am J Gastroenterol; 2013 Dec; 108(12):1824-30. PubMed ID: 24300857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
    Kwon JH; Farrell RJ
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
    Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of immunosuppressants and biologicals in patients with previous cancer.
    Beaugerie L
    Dig Dis; 2013; 31(2):254-9. PubMed ID: 24030236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Cosnes J
    Dig Dis; 2017; 35(1-2):50-55. PubMed ID: 28147366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
    Lee J; Clarke K
    Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?
    Lakatos PL; Miheller P
    Curr Drug Targets; 2010 Feb; 11(2):179-86. PubMed ID: 20210767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do inflammatory bowel disease therapies cause cancer?
    Mason M; Siegel CA
    Inflamm Bowel Dis; 2013 May; 19(6):1306-21. PubMed ID: 23470503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
    Kopylov U; Vutcovici M; Kezouh A; Seidman E; Bitton A; Afif W
    Inflamm Bowel Dis; 2015 Aug; 21(8):1847-53. PubMed ID: 25993693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
    Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
    J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.